Ovulatory disorders and infertility

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 51, Issue 4 SUPPL., 2006, Pages 267-282

  Urman, Bulent ^a   Yakin, Kayhan ^a  

^a AMERICAN HOSPITAL   (Turkey)

Author keywords

Infertility, female; Ovulation; Ovulatory disorders

Indexed keywords

ALBUMIN; ANDROGEN; AROMATASE INHIBITOR; BROMOCRIPTINE; CABERGOLINE; CLOMIFENE CITRATE; DEXAMETHASONE; DOPAMINE RECEPTOR STIMULATING AGENT; FOLLITROPIN; GLUCOCORTICOID; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN DERIVATIVE; GONADOTROPIN; HETASTARCH; HUMAN MENOPAUSAL GONADOTROPIN; INSULIN SENSITIZING AGENT; LUTEINIZING HORMONE; METFORMIN; ORAL CONTRACEPTIVE AGENT; RECOMBINANT FOLLITROPIN; RECOMBINANT LUTEINIZING HORMONE; SULFONYLUREA DERIVATIVE;

ADOPTION; ANOVULATION; CAUTERIZATION; CLINICAL TRIAL; CONFERENCE PAPER; CYST; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; HYPOGLYCEMIA; HYPOGONADOTROPIC HYPOGONADISM; INFERTILITY THERAPY; INSULIN RESISTANCE; LAPAROSCOPIC OVARIAN DRILLING; LAPAROSCOPIC SURGERY; LIFESTYLE; MULTIPLE PREGNANCY; NAUSEA; OVARY HYPERSTIMULATION; OVARY INSUFFICIENCY; OVARY POLYCYSTIC DISEASE; OVULATION; PATIENT COUNSELING; PREGNANCY RATE; PRIORITY JOURNAL; SPONTANEOUS ABORTION; VOMITING; WEIGHT REDUCTION; WORLD HEALTH ORGANIZATION;

ANOVULATION; CLOMIPHENE; FEMALE; FERTILITY AGENTS, FEMALE; GLUCOCORTICOIDS; GONADOTROPIN-RELEASING HORMONE; GONADOTROPINS; HUMANS; HYPERPROLACTINEMIA; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; METFORMIN; OVARIAN DISEASES; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; WORLD HEALTH ORGANIZATION;

EID: 33646460791     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (129)

1. Hull M, Glazener C, Kelly N, et al: Population study of causes, treatment, and outcome of infertility. Br Med J 1985;291:1693-1697
2. Collins JL: Unexplained infertility. In Infertility: Evaluation and Treatment. Edited by W Keye, R Chang, R Rebar, et al: Philadelphia, WB Saunders, 1995, pp 249-262
3. Insler V, Melmed H, Mashiah S, et al: Functional classification of patients selected for gonadotropin therapy. Obstet Gynecol 1968;32:620-626
4. The Eshre Capri Workshop Group: Anovulatory infertility. Hum Reprod 1995;10:1549-1553
5. Rowe P, Comhaire F, Hargreave, T et al: Female partner. In WHO Manual for the Standardized Investigation and Diagnosis of the Infertile Couple. Cambridge, Cambridge Press Syndicate of University of Cambridge, 2000, pp 40-67
6. Santbrink E, Hop W, Fauser BC: Classification of normogonadotropic infertility: Polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovarian syndrome. Fertil Steril 1995;67:452-458
7. Schoot B, Coelingh-Bennink H, Mannaerts B, et al: Human recombinant follicle stimulating hormone induces growth of preovulatory follicles without concomitant increase in androgen and oestrogen biosynthesis in a women with isolated gonadotrophin deficiency. J Clin Endocrinol Metab 1992;74:1471-1473
8. Martin K, Hall J, Adams J: Comparison of exogenous gonadotropins and pulsatile gonadotropin releasing hormone for induction of ovulation in hypogonadotropic amenorrhea. J Clin Endocrinol Metab 1993;77:125-129
9. Dale O, Tanbo T, Henrikson T, et al: Gonadotropin therapy for female infertility. Acta Endocrinol (Copenh) 1989;120:395-399
10. Lunenfeld B, Eshkol A: Induction of ovulation with gonadotropins. In Follicular Maturation and Valuation. Edited by R Rolland, E Van Hall, S Hillier, et al. Amsterdam, Excerpta Medica International Congress Series, 1982, pp 361-379
11. Hamilton-Fairley D, Franks S: Common problems in induction of ovulation. Baillieres Clin Obstet Gynecol 1990;4:609-625
12. Fluker MR, Urman B, Mackinnon M, et al: Exogenous gonadotropin therapy in World Health Organization groups I and II ovulatory disorders. Obstet Gynecol 1994;83:189-196
13. Stein I, Leventhal M: Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-191
14. Stein I, Cohen M: Surgical treatment of bilateral polycystic ovaries. Am J Obstet Gynecol 1939;38:465-473
15. Knochenhauer ES, Key T, Kahsar-Miller M, et al: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998;83:3078-3082
16. Asuncion M, Calvo R, San Millian J, et al: A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women in Spain. J Clin Endocrinol Metab 2000;85:2434-2438
17. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group: Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-47
18. Adams J, Poison D, Franks S: Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J Clin Res 1986;293:355-359
19. Laven JS, Imani B, Eijkemans M, et al: New approaches to PCOS and other forms of anovulation. Obstet Gynecol Surv 2002;57:755-767
20. Vermeulen A, Verdonck L, Kaufman J: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-3672
21. Balen A, Laven JS, Tan S, et al: Ultrasound assessment of the polycystic ovary: International consensus definitions. Hum Reprod Update 2003;9:493-504
22. Dewailly D, Robert Y, Helin I, et al: Ovarian stromal hypertrophy in hyperandrogenic women. Clin Endocrinol 1994;41:557-562
23. Bucket W, Bouzayen R, Watkin K, et al: Ovarian stromal echogenicity in women with normal and polycystic ovaries. Hum Reprod 2003;18:598-603
24. Dunaif A, Segal K, Futterweit W, et al: Profound peripheral insulin resistance, independent of obesity in polycystic ovary syndrome. Diabetes 1989;38:1165-1174
25. Knowler W, Barrett-Connor E, Fowler S, et al: Reduction in the incidence of type 2 diabetes with life style intervention or metformin. N Engl J Med 2002;346:393-403
26. Buchanan T, Xiang A, Peters R, et al: Preservation of pancreatic beta cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk hispanic women. Diabetes 2002;51:2796-2803
27. Tarlatzis B, Grimbizis G, Pournaropoulos F, et al: The prognostic value of basal LH/FSH ratio in the treatment of patients with PCOS with assisted reproduction. Hum Reprod 1995;10:2545-2549
28. Balen A, Conway G, Kaltsas G, et al: Polycystic ovary syndrome: The spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-2111
29. Grodstein F, Goldman M, Cramer D: Body mass index and ovulatory infertility. Epidemiology 1994;5:247-250
30. Guzick D, Wing R, Smith D, et al: Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994;61:598-604
31. Bates G, Whitworth N: Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil Steril 1982;38:406-409
32. Norman R, Davies M, Lord J, et al: The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002;13:251-257
33. Clark A, Thornley B, Galletley C, et al: Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995;10:2705-2712
34. Huber-Buschholz M, Carey D, Norman RJ: Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-1474
35. Clark A, Thornley B, Tomlinson L, et al: Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998;13:1502-1505
36. Mayer-Davis E, D'Agostino R, Karter A, et al: Intensity and amount of physical activity in relation to insulin sensitivity: The insulin resistance atherosclerosis study. JAMA 1999;279:669-674
37. Bates G, Whitworth N: Effect of body weight reduction on plasma androgens in obese infertile women. Fertil Steril 1982;38:406-409
38. Ciampelli M, Fulghesu A, Cucinelli F, et al: Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metabolism 1999;48:167-172
39. Evans D, Hoffman R, Kalkhoff R, et al: Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 1983;57:304-310
40. Meirow D, Yossepowitch O, Rosler A, et al: Insulin resistant and nonresistant women represent two clinical and endocrinological subgroups. Hum Reprod 1995;10:1951-1956
41. Practice Committee of the American Society for Reproductive Medicine: Use of clomiphene citrate in women. Fertil Steril 2003;80:1302-1308
42. Clark J, Markaverich B: The agonist-antagonist properties of clomiphene: A review. Pharmacol Ther 1982;15:467-519
43. Kerin J, Liu J, Phillipou G, et al: Evidence for a hypothalamic site of action of clomiphene citrate in women. J Clin Endocrinol Metab 1985;61:265-268
44. Kettel L, Roseff S, Berga S, et al: Hypothalamic pituitary ovarian response to clomiphene citrate in women with polycystic ovary syndrome. Fertil Steril 1993;59:532-538
45. Imani B, Eijkemans M, Te Velde E, et al: Predictors of patients remaining anovulatory during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. J Clin Endocrinol Metab 1998;84:1617-1622
46. Imani B, Eijkemans M, Te Velde E, et al: Predictors of chances to conceive in ovulatory patients during clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. J Clin Endocrinol Metab 1998;84:1617-1622
47. Wu C, Winkel C: The effect of therapy initiation day on the clomiphene citrate therapy. Fertil Steril 1989;52:564-568
48. Derman S, Adashi E: Induction of ovulation. Compr Ther 1995;21:583-589
49. Dodge S, Strickler R, Keller D: Ovulation induction with low doses of clomiphene citrate. Obstet Gynecol 1986;67:63S-65S
50. Lobo R, Granger L, Davajan V, et al: An extended regimen of clomiphene citrate in women unresponsive to standard therapy. Fertil Steril 1982;37:762-766
51. Hughes E, Collins J, Vandekerckhove P: Clomiphene citrate for ovulation induction in women with oligoamenorrhea. Cochrane Database Syst Rev 2001;4:CD000057
52. Smith Y, Randolph J, Christman GM, et al: Comparison of low technology and high technology monitoring of clomiphene citrate induced ovulation. Fertil Steril 1998;70:165-168
53. Pritts E: Treatment of the infertile patient with polycystic ovarian syndrome. Obstet Gynecol Surv 2002;57:587-597
54. Gelety TJ, Buyalos RP: The effect of clomiphene citrate and menopausal gonadotropins on cervical mucus in ovulatory cycles. Fertil Steril 1993;60:471-476
55. Massai MR, de Ziegler D, Lesobre V, et al: Clomiphene citrate affects cervical mucus and endometrial morphology independently of the changes in plasma hormonal levels induced by multiple follicular recruitment. Fertil Steril 1993;59:1179-1186
56. Eden J, Place J, Carter G, et al: The effect of clomiphene citrate on follicular phase increase in endometrial thickness and uterine volume. Obstet Gynecol 1989;73:187-190
57. Dickey R, Olar T, Taylor S, et al: Relationship of endometrial thickness and pattern of fecundity in ovulation cycles: Effect of clomiphene citrate alone and with human menopausal gonadorropin. Fertil Steril 1993;59:756-760
58. Eijkemans MJ, Habbema JD, Fauser BC: Characteristics of the best prognostic evidence: An example on prediction of outcome after clomiphene citrate induction of ovulation in normogonadotropic oligomenorrheic infertility. Semin Reprod Med 2003;21:39-47
59. Branigan EF, Estes MA: A randomized clinical trial of treatment of clomiphene citrate-resistant anovulation with the use of oral contraceptive pill suppression and repeat clomiphene citrate treatment. Am J Obstet Gynecol 2003;188:1424-1428, discussion 1429-1430
60. Loughlin T, Cunningham S, Moore A, et al: Adrenal abnormalities in polycystic ovary syndrome. 1986;62:142-144
61. Daly D, Walters C, Soto-Albors C, et al: A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 1984;41:844-848
62. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. Br Med J 2003;327:951-953
63. Fleming R, Hopkinson Z, Wallace A, et al: Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002;87:569-574
64. Jakubowicz D, Seppala M, Jakubowicz S, et al: Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001;86:1126-1133
65. Nestler J, Jakubowicz D: Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623
66. Nestler J, Jakubowicz D, Evans W, et al: Effects of metformin on spontaneous and clomiphene induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;1:1876-1880
67. Ng E, Wat N, Ho P: Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene resistant polycystic ovaries: Randomized double blinded placebo controlled trial. Hum Reprod 2001;16:1625-1631
68. Vandermolen D, Ratts D, Evans W, et al: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-315
69. Yarali H, Yildiz B, Demirol A, et al: Co-administration of metformin during rFSH treatment in patients with clomiphene citrate resistant polycystic ovarian syndrome: A prospective randomized trial. Hum Reprod 2002;17:289-294
70. Kocak M, Caliskan E, Simsir C, et al: Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate resistant women with polycystic ovary syndrome. Fertil Steril 2002;77:101-106
71. Malkawi H, Qublan H: The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene resistant women with polycystic ovary syndrome. Saudi Med J 2002;23:663-666
72. El-Biely M, Habba M: The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertil Soc J 2001;6:43-49
73. Moghetti P, Castello R, Negri C, et al: Metformin effects on clinical features, endocrine and metabolic profiles and insulin sensitivity in polycystic ovary syndrome: A randomized double blind placebo controlled six month trial followed by open long term clinical evaluation. J Clin Endocrinol Metab 2000;85:139-146
74. Pasquali R, Gambineri A, Biscotti D, et al: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:2767-2774
75. Glueck CJ, Phillips H, Cameron D, et al: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first trimester spontaneous abortion: A pilot study. Fertil Steril 2001;75:46-52
76. Urman B, Pride SM, Ho Yuen B: Management of overstimulated gonadotropin cycles with a controlled drift period. Hum Reprod 1992;7:213-217
77. Fauser BC, Donderwinkel P, Schoot D: The step down principle in gonadotropin treatment and the role of GnRH analogues. Baillieres Clin Obstet Gynecol 1993;7:309-330
78. Farhi J, Homburg R, Lerner A, et al: The choice of treatment for anovulation associated with polycystic ovary syndrome following failure to conceive with clomiphene. Hum Reprod 1993;8:1367-1371
79. Homburg R, Levy T, Ben Rafael Z: A comparative prospective study of conventional regimen with chronic low dose administration of follicle stimulating hormone for anovulation associated with polycystic ovary syndrome. Fertil Steril 1995;63:729-733
80. Macklon N, Imani B, Fauser BC: Optimizing protocols for ovulation induction. In Female Infertility Therapy. Edited by Z Shoham, C Howles, H Jacobs. London, Martin Dunitz Ltd, 1999, pp 75-83
81. Hedon B, Hughes C, Emperaire J, et al: A comparative prospective study of a chronic low dose versus a conventional ovulation stimulation regimen using recombinant human follicle stimulating hormone in anovulatory infertile women. Hum Reprod 1998;13:2688-2692
82. Homburg R, Howles C: Low dose FSH therapy for anovulatory infertility associated with polycystic ovary syndrome: Rationale, reflections and refinements. Hum Reprod Update 1999;5:493-499
83. Schoot B, Hop DC, Jong F, et al: Initial estradiol response predicts outcome of exogenous gonadotrophins using a step-down regimen for induction of ovulation in PCOS. Fertil Steril 1995;64:1081-1087
84. van Santabrink E, Fauser BC: Urinary follicle stimulating hormone for normogonadotropic clomiphene citrate resistant anovulatory infertility: Prospective randomized comparison between low dose step up and step down regimens. J Clin Endocrinol Metab 1997;82:3597-3602
85. Nugent D, Vanderkerckhove P, Hughes E, et al: Gonadotrophin therapy for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev 2001;4:CD00390
86. van Wely M, Bayram N, van der Meen F: Recombinant FSH in alternative doses versus urinary gonadotropins for ovulation induction in subfertility associated with polycystic ovary syndrome: A systematic review based on a Cochrane review. Hum Reprod 2003;18:1143-1149
87. Hugues J, Bstandig B, Bry-Gauillard H, et al: Comparison of the effectiveness of recombinant and urinary FSH preparations in the achievement of follicular selection in chronic anovulation. Reprod Biomed Online 2001;3:195-198
88. Coelingh-Bennink H, Fauser BC, Out H: Recombinant follicle stimulating hormone (FSH; Puregon) is more efficient than urinary FSH (Metrodin) in women with clomiphene citrate resistant, normogonadotropic chronic anovulation: A prospective, multicenter, assessor-blind, randomized, clinical trial. Fertil Steril 1998;69:19-27
89. Hompes P, van Weissenburch M, Burger C, et al: The additional use of buserelin in hMG ovulation induction in PCO: A double blind controlled study. Prog Clin Biol Res 1986;225:391-399
90. Fleming R, Coutts J: LH/RH analogs for ovulation induction with particular reference to polycystic ovary syndrome. Baillieres Clin Obstet Gynecol 1988;2:677-687
91. Homburg R, Eshel A, Kilborn J, et al: Combined luteinizing hormone releasing hormone analogue and exogenous gonadotrophins for treatment of infertility associated with polycystic ovaries. Hum Reprod 1990;5:32-35
92. Bachus K, Hughes C, Haney A, et al: Luteal phase in polycystic ovary syndrome during ovulation induction with human menopausal gonadotrophin with and without leuprolide acetate. Fertil Steril 1990;54:27-31
93. Homburg R, Berkowitz K, Levy T, et al: In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril 1993;60:858-863
94. Scheele F, Hompes P, van der Meer M, et al: The effects of a gonadotropin releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome. Hum Reprod 1993;8:699-704
95. Dale O, Tanbo T, Haug E, et al: The impact of insulin resistance on the outcome of ovulation induction with low-dose follicle stimulating hormone in women with polycystic ovary syndrome. Hum Reprod 1998;13:567-570
96. White D, Polson D, Kiddy D, et al: Induction of ovulation with low dose gonadotropins in polycystic ovary syndrome: An analysis of 109 pregnancies in 225 women. J Clin Endocrinol Metab 1996;81:3821-3824
97. Homburg R, Insler VL: Ovulation induction in perspective. Hum Reprod Update 2002;8:449-462
98. Grudzinskas J, Egbase P: Prevention of OHSS: Novel strategies. Hum Reprod 1998;13:2051-2053
99. Chen D, Burmeister L, Goldschlag D, et al: Ovarian hyperstimulation syndrome: Strategies for prevention. Reprod Biomed Online 2003;7:43-49
100. Yarali H, Bukulmez O, Gurgan TL: Urinary follicle stimulating hormone (FSH) versus recombinant FSH in clomiphene citrate resistant normogonadotropic chronic anovulation: A prospective randomized study. Fertil Steril 1999;72:276-281
101. Donesky B, Adashi E: Surgically induced ovulation in the polycystic ovary syndrome: Wedge resection revisited in the age of laparoscopy. Fertil Steril 1995;63:439-463
102. Gjonnaess H: Polycystic ovarian syndrome treated by ovarian electrocautery through the laparoscope. Fertil Steril 1984;49:956-960
103. Balen AH: Hypersecretion of luteinizing hormone and the polycystic ovary syndrome. Hum Reprod (suppl 2) 1993;8:123-128
104. Wang JX, Davies MJ, Norman RJ: Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment. Hum Reprod 2001;16:2606-2609
105. Wang CF, Gemzell C: The use of human gonadotropins for the induction of ovulation in women with polycystic ovarian disease. Fertil Steril 1980;33:479-486
106. Hamilton-Fairley D, Kiddy D, Watson H, et al: Low dose gonadotropin therapy for induction of ovulation in 100 women with polycystic ovary syndrome. Hum Reprod 1991;6:1095-1099
107. Farquhar C, Vanderkerckhove P, Lilford R: Laparoscopic drilling by diathermy of laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 2001;4:CD001122
108. Bayram N, van Wely M, Kaaijk E, et al: Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: Randomized controlled trial. Br Med J 2004;328:192-196
109. Naether O, Baukloh V, Fischer R, et al: Long term follow-up in 206 infertility patients with polycystic ovary syndrome after laparoscopic electrocautery of the ovarian surface. Hum Reprod 1994;9:2342-2349
110. Gjonnaess H: Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril 1998;69:697-701
111. Amer SA, Banu Z, Li TC, et al: Long-term follow-up of patients with polycystic ovary syndrome after laparoscopic ovarian drilling: Endocrine and ultrasonographic outcomes. Hum Reprod 2002;17:2851-2857
112. American College of Obstetricians and Gynecologists: Management of infertility caused by ovulatory dysfunction. Obstet Gynecol 2002;99:347-358
113. van Kasteren Y, Hoek A, Schoemaker J. Ovulation induction in premature ovarian failure: A placebo controlled trial combining pituitary suppression with gonadotrophin stimulation. Fertil Steril 1995;64:273-278
114. Molitch M: Manifestations, epidemiology and pathogenesis of prolactinomas in women. In Prolactinomas. Edited by J Olefsky, R Robbins. New York, Churchill Livingstone, 1986, pp 67-95
115. Archer D: Prolactin response to thyrotropin releasing hormone in women with infertility and/or randomly elevated serum prolactin levels. Fertil Steril 1987;47:559-564
116. Lenton E, Suleiman R, Sobowale O, et al: The human menstrual cycle plasma concentrations of prolactin, LH, FSH, estradiol, and progesterone in conceiving and nonconceiving women. J Reprod Fertil 1982;65:131-139
117. Strachan M, Teoh W, Don-Wauchope A, et al: Clinical and radiological features of patients with macroprolactinemia. Clin Endocrinol 2003;59:339-346
118. Suliman A, Smith T, Gibney J, et al: Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: Application of a new strict laboratory definition of macroprolactinemia. Clin Chem 2003;49:1504-1509
119. Toldy E, Locsei Z, Szabolcs I, et al: Macroprolactinemia: The consequence of a laboratory pitfall. Endocrine 2003;22:267-274
120. Schlechte J. Clinical practice: Prolactinoma. N Engl J Med 2003;20:2035-2041
121. Ferrari C, Rampini P. Functional characterization of hypothalamic hyperprolactinemia. J Clin Endocrinol Metab 1982;55:897-901
122. Serri O, Chik C, Ur E, et al: Diagnosis and management of hyperprolactinemia. Can Med Assoc J 2003;16:575-581
123. Ferrari C, Crosignani PG: Medical treatment of hyperprolactinemic disorders. Hum Reprod 1986;1:507-514
124. Weil C: The safety of bromocriptine in hyperprolactinemic female infertility: A literature review. Curr Med Res Opin 1986;10:172-195
125. Murphy F, Vesely D, Jordan RM, et al: Giant invasive prolactinomas. Am J Med 1987;83:995-1002
126. Pellegrini I, Rasolonjanahary R, Gunz G, et al: Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989;69:500-509
127. Crosignani PG: Anovulatory infertility associated with hyperprolactinaemia. in Gonadotrophins and Fertility in Women. Edited by EY Adashi, DT Baird, PG Crosignani. Serono Fertility Series. Third volume. Serono, Rome, 1999, pp 61-71
128. Del Dotto P, Bonuccelli U: Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 2003;42:633-645
129. Laws EJ: Pituitary surgery. Endocrinol Metab Clin North Am 1987;16:647-665